美國Osmetech  www.osmetech.com
美國Osmetech公司 OPTI血氣、電解質分析儀
Osmetech, Molecular Diagnostics
Osmetech plc is an AIM-listed public company on the London Stock Exchange under ticker symbol OMH. Osmetech plc is incorporated in England and Wales and its main country of operations is the US.
 
Osmetech plc was founded in 1993, developing electronic odour sensor (“e-nose”) technology. IPO followed in 1994 and in 1999, the Company changed its name from Aromascan to Osmetech refocusing the business on the opportunities within the global healthcare market. With the acquisition of the OPTI (blood gas) product line from Roche Diagnostics in 2003, the Critical Care Diagnostic Division was formed, which more than doubled its level of sales revenues in 3 years through a strong network of international distributors.
 
The Osmetech Molecular Diagnostics division was created from acquisitions of Molecular Sensing plc in October 2004 and Clinical Micro Sensors, Inc. from Motorola in July 2005. Recently, Osmetech divested its Critical Care Diagnostic Division and is now focused on accelerating the expansion and development of the Molecular Diagnostic Division.
 
Osmetech Molecular Diagnostics
 
Transforming molecular diagnostics into practical, cost-effective testing solutions.
 
As the demand for and acceptance of molecular diagnostic tests multiplies, so does the rate of testing decentralization. The movement of molecular diagnostic testing into the clinical laboratories of mid-size hospitals requires greater simplicity, flexible testing capabilities, and cost-effectiveness.
 
Osmetech Molecular Diagnostics is focused on providing cutting-edge, cost-effective molecular diagnostic technologies and tools that enable a broader range of hospitals and laboratories to offer molecular diagnostic services for improved patient care.